Cellular experiments on RAW264.7 (macrophage cell line) confirmed the anti-inflammatory and anti-osteoclast properties of MHP1, indicating that it could be a valid therapeutic drug in ischemic stroke, and is also able to contrast osteoporosis that is linked to poor prognosis in ischemic stroke [24]. Here, CACNA1A is linked to ischemic stroke.